Pyrazolam

1. 2026-10-19issueIssued info_card
2. 2026-10-02srcDetectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays
3. 2026-10-02srcThe emergence of new psychoactive substance (NPS) benzodiazepines: A review.
4. 2026-10-02srcHuman urinary metabolic patterns of the designer benzodiazepines flubromazolam and pyrazolam studied by liquid chromatography-high resolution mass spectrometry
5. 2026-10-02srcIn vitro glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases
6. 2026-10-02srcDetection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics
7. 2026-10-02srcDesigner benzodiazepines: A new challenge
8. 2026-10-02srcCharacterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine
9. 2026-10-02srcThe blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines
10. 2026-10-02srcAn unusual way of acute Pyrazolam poisoning in consumer of commercially approved benzodiazepines
11. 2026-10-02srcAssessment of the Availability, Cost, and Motivations for Use over Time of the New Psychoactive Substances-Benzodiazepines Diclazepam, Flubromazepam, and Pyrazolam-in the UK
12. 2026-10-02srcUrine analysis of 28 designer benzodiazepines by liquid chromatography-high-resolution mass spectrometry
13. 2026-10-02srcBlood concentrations of new designer benzodiazepines in forensic cases.
14. 2026-10-02srcOrgan distribution of diclazepam, pyrazolam and 3-fluorophenmetrazine
15. 2026-10-02srcBenzodiazepines and Related Sedatives.
16. 2026-10-02srcSubtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update
17. 2026-10-02srcIn vitro γ-aminobutyric acid A (GABAA) receptor activity and binding interactions at the α+/γ2– interface of 53 prescription and designer benzodiazepines
18. 2026-10-02srcClinical detoxification of bromazolam using diazepam: a case report
19. 2026-10-02srcOccurrence and time course of NPS benzodiazepines in Sweden - results from intoxication cases in the STRIDA project.
20. 2026-10-02srcDesigner benzodiazepines: a report of exposures recorded in the National Poison Data System, 2014-2017.
21. 2026-10-02srcThe Evolution Toward Designer Benzodiazepines in Drug-Facilitated Sexual Assault Cases
22. 2026-10-02srcFast and Sensitive Method for the Determination of 17 Designer Benzodiazepines in Hair by Liquid Chromatography-Tandem Mass Spectrometry
23. 2026-10-02src'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports
24. 2026-10-02src8-Substituted Triazolobenzodiazepines: In Vitro and In Vivo Pharmacology in Relation to Structural Docking at the α1 Subunit-Containing GABAA Receptor
25. 2026-10-02srcBenzodiazepine Boom: Tracking Etizolam, Pyrazolam, and Flubromazepam from Pre-UK Psychoactive Act 2016 to Present Using Analytical and Social Listening Techniques
26. 2026-10-02srcUS Patent 3,954,728: Preparation of 6-pyridyl-4H-triazolo[4,3-a][1,4]benzodiazepines
27. 2026-10-02srcPhysical properties of pyrazolam (CAS 39243-02-2)
28. 2026-09-04issueIssued emergency
29. 2026-09-04issueIssued info_card
30. 2026-09-04issueIssued notice
31. 2026-07-03proposaldependence · taper
32. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
33. 2026-06-04publicationPublication — backfill
34. 2026-05-09revisionRevision 1
35. 2026-05-09absenceSearched ClinicalTrials.gov for "pyrazolam" — no results
36. 2026-05-09absenceSearched PubMed for "pyrazolam synthesis Fryer triazolo benzodiazepine 1980s" — no results
37. 2026-05-09genGeneration — pipeline-v5 · with 3 morepipeline-v5
38. 2026-05-09rungeneration run

The same entries, as forms: six forms.